Information update

Update: All Marketed Sibutramine Drugs Voluntarily Withdrawn in Canada

Starting date:
October 13, 2010
Posting date:
October 13, 2010
Type of communication:
Information Update
Subcategory:
Drugs
Source of recall:
Health Canada
Issue:
Product Safety
Audience:
General Public
Identification number:
RA-110003834

Further to Health Canada's October 8, 2010, communication on the voluntary recall by Abbott Laboratories of Meridia® (the brand name for the weight-loss drug sibutramine), Health Canada is updating healthcare practitioners and Canadians with respect to the two generic forms of sibutramine drugs authorized in Canada: Apo-sibutramine and Novo-sibutramine.

Apotex Inc., the manufacturer of Apo-sibutramine, has agreed to voluntarily withdraw this drug from the Canadian market. Teva Canada Ltd., the manufacturer of Novo-sibutramine, has confirmed to Health Canada that it has not marketed this drug in Canada, i.e., Novo-sibutramine is not available for sale on the Canadian market.

As with Meridia®, patients currently taking Apo-sibutramine should contact their healthcare practitioner at their earliest convenience regarding potential alternatives. Pharmacists with questions regarding their current supply of Apo-sibutramine should contact Apotex Inc. directly at 1-877-427-6839 (1-877-4-APOTEX), extension 1601. Patients with questions regarding their current supply should contact their pharmacist.

Media enquiries

Health Canada
613-957-2983

Public enquiries

613-957-2991
1-866-225-0709